# Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial

> **NCT06126588** · PHASE2 · RECRUITING · sponsor: **Central Hospital, Nancy, France** · enrollment: 28 (estimated)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT06126588
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-29
- **Primary completion:** 2026-03-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126588, "Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06126588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*